Yoshihara Hiroyuki, Yoneoka Daisuke
Department of Orthopaedic Surgery, NYU Hospital for Joint Diseases, 301 E. 17th St, New York, NY 10003, USA; Department of Orthopaedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.
Department of Statistical Sciences, School of Advanced Sciences, The Graduate University for Advanced Studies, 10-3 Midori-cho, Tachikawa, Tokyo 190-8562, Japan.
Spine J. 2014 Sep 1;14(9):1844-9. doi: 10.1016/j.spinee.2013.11.029. Epub 2013 Nov 27.
Surgical treatment for spinal metastasis is still controversial. However, with the improvements in treatment for primary tumors, the survival rate of patients with spinal metastasis is enhanced. At the same time, surgical technique for spinal metastasis has also improved.
The purpose of this study was to examine trends in the surgical treatment for spinal metastasis and in-hospital patient outcomes on a national level.
STUDY DESIGN/SETTING: This was an epidemiologic study using national administrative data from the Nationwide Inpatient Sample (NIS) database.
All discharges in the NIS with a diagnosis code of secondary malignant neoplasm of the spinal cord/brain, meninges, or bone who also underwent spinal surgery from 2000 to 2009 were included.
Trends in the surgical treatment for spinal metastasis, in-hospital complications and mortality, and resource use were analyzed.
The NIS was used to identify patients who underwent surgical treatment for spinal metastasis from 2000 to 2009, using the International Classification of Diseases, Ninth revision, Clinical Modification codes. Trends in the surgical treatment for spinal metastasis and in-hospital patient outcomes were analyzed.
From 2000 to 2009, there was an increasing trend in the population growth-adjusted rate of surgical treatment for spinal metastasis (1.15-1.77 per 100,000; p<.001). Average Elixhauser comorbidity score increased over time (2.6-3.8; p<.001), and the overall in-hospital complication rate increased over time (14.8%-27.7%; p<.001), whereas in-hospital mortality rate and length of hospital stay remained stable over time (5.2%-4.6%, p=.413; 10.6-10.8 days, p=.626). Inflation-adjusted mean hospital charges increased more than two-fold over time ($50,390-$110,173; p<.001).
During the last decade, surgical treatment for spinal metastasis has increased in the United States. The overall in-hospital complication rate and hospital charges increased, whereas the in-hospital mortality rate and length of hospital stay remained stable.
脊柱转移瘤的外科治疗仍存在争议。然而,随着原发性肿瘤治疗方法的改进,脊柱转移瘤患者的生存率有所提高。同时,脊柱转移瘤的手术技术也有所进步。
本研究旨在探讨全国范围内脊柱转移瘤外科治疗的趋势及住院患者的治疗结果。
研究设计/研究地点:这是一项利用全国住院患者样本(NIS)数据库中的国家行政数据进行的流行病学研究。
纳入2000年至2009年期间在NIS中诊断为脊髓/脑、脑膜或骨继发性恶性肿瘤且接受脊柱手术的所有出院患者。
分析脊柱转移瘤外科治疗的趋势、住院并发症和死亡率以及资源利用情况。
利用NIS,通过国际疾病分类第九版临床修订本编码识别2000年至2009年期间接受脊柱转移瘤手术治疗的患者。分析脊柱转移瘤外科治疗的趋势及住院患者的治疗结果。
2000年至2009年,经人口增长调整后的脊柱转移瘤手术治疗率呈上升趋势(每10万人中1.15 - 1.77例;p <.001)。随着时间推移,平均艾利克豪泽合并症评分升高(2.6 - 3.8;p <.001),总体住院并发症发生率随时间增加(14.8% - 27.7%;p <.001),而住院死亡率和住院时间随时间保持稳定(5.2% - 4.6%,p =.413;10.6 - 10.8天,p =.626)。经通胀调整后的平均住院费用随时间增加了两倍多(50,390美元 - 110,173美元;p <.001)。
在过去十年中,美国脊柱转移瘤的外科治疗有所增加。总体住院并发症发生率和住院费用增加,而住院死亡率和住院时间保持稳定。